Shire Plc (SHP) has settled a patent lawsuit against Teva Pharmaceutical Industries Ltd. (TEVA). This paves the way for lower-cost generic versions of Intuniv, used to treat attention deficit hyperactivity disorder (ADHD).
Israel based Teva is the world’s largest generic-drug company. According to a statement from Shire, Teva will market a generic version of the Intuniv under license. The license will take effect once another generic-drug maker, Actavis Inc. (ACT), has sold the drug for six months starting in December 2014.
Shire sued Teva, based in Petach Tikva, Israel, in federal court in Wilmington, Delaware, in April 2010 alleging infringement of two patents for Intuniv. Shire previously settled with Parsippany, New Jersey-based Actavis over the patents. A trial of the litigation against Teva and Actavis was held in September.
The case is Shire LLC v. Teva Pharmaceuticals USA Inc., 10-cv-00329, U.S. District Court, District of Delaware (Wilmington).